Titan Pharmaceuticals (NASDAQ:TTNP) vs. Silexion Therapeutics (NASDAQ:SLXN) Head-To-Head Analysis

Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Volatility and Risk

Titan Pharmaceuticals has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Silexion Therapeutics has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500.

Profitability

This table compares Titan Pharmaceuticals and Silexion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Titan Pharmaceuticals	N/A	-118.01%	-103.79%
Silexion Therapeutics	N/A	N/A	-249.43%

Analyst Recommendations

This is a summary of recent recommendations for Titan Pharmaceuticals and Silexion Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Titan Pharmaceuticals	0	0	0	0	0.00
Silexion Therapeutics	0	0	1	0	3.00

Silexion Therapeutics has a consensus price target of $5.00, indicating a potential upside of 479.58%. Given Silexion Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Silexion Therapeutics is more favorable than Titan Pharmaceuticals.

Earnings and Valuation

This table compares Titan Pharmaceuticals and Silexion Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Titan Pharmaceuticals	$180,000.00	19.12	-$5.57 million	($5.21)	-0.72
Silexion Therapeutics	N/A	N/A	$260,000.00	N/A	N/A

Silexion Therapeutics has lower revenue, but higher earnings than Titan Pharmaceuticals.

Insider and Institutional Ownership

31.5% of Titan Pharmaceuticals shares are held by institutional investors. Comparatively, 10.9% of Silexion Therapeutics shares are held by institutional investors. 24.9% of Titan Pharmaceuticals shares are held by insiders. Comparatively, 33.0% of Silexion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Silexion Therapeutics beats Titan Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.